Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma
Sponsor: Atara Biotherapeutics
A PHASE1 clinical study on Malignant Pleural Mesothelioma (MPM), this trial is ongoing. The trial is conducted by Atara Biotherapeutics and has accumulated 15 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Aug 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 10 earlier versions
-
Sep 2023 — Jun 2024 [monthly]
Recruiting PHASE1
-
Jan 2023 — Sep 2023 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Nov 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Jun 2022 [monthly]
Recruiting PHASE1
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Atara Biotherapeutics
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .